President Donald Trump purchased between $1 million and $5 million in Axon Enterprise (AXON) stock on February 10, 2026 — just 14 days before U.S. Immigration and Customs Enforcement posted a notice seeking a five-year, $220 million contract for roughly 17,800 Tasers, unlimited cartridges, and full officer training. The disclosure surfaced in Trump’s Office of Government Ethics filing made public in May, which contained over 3,700 individual transactions. The timing has drawn sharp scrutiny from ethics experts and renewed investor attention to Axon’s rapidly expanding federal business.
Axon dominates the U.S. Taser market with approximately 90% market share, according to investment firm Brown Advisory, and already has active supply relationships with federal law enforcement. The ICE notice, while not naming Axon by name, calls for “conductive-energy weapons” with specs — a 45-foot range, 10 individually targeted probes, and an upgrade from the older “X26P/X2” platform to the “T10” — that procurement reviewers and three independent policing experts told CNBC match only Axon’s flagship Taser 10 model. If awarded, the contract would more than quadruple ICE’s current Taser inventory. Axon has been aggressively building its federal footprint: the company spent nearly $2.5 million on lobbying in 2025 and hired a former senior Palantir executive to spearhead its government business unit.
For retail investors watching AXON, the story is nuanced. On one hand, this underscores Axon’s status as the de facto sole-source supplier to federal law enforcement — a competitive moat that is extremely difficult to dislodge. On the other hand, Congressional scrutiny of the presidential disclosure creates headline risk and could trigger short-term volatility. The White House maintains that Trump’s assets are managed by an independent third-party trust and that “there are no conflicts of interest.” The $220 million contract has not yet been formally awarded. Investors should monitor the contract award announcement closely: a confirmed deal would provide a material boost to Axon’s government revenue segment, which has been among the fastest-growing parts of its business. A prolonged ethics controversy could, however, add noise — even if the fundamental case for Axon as a government technology supplier remains intact.
